PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34368251-11 2021 The data of ApoE-/- mice showed that increased plasma lipids and aggravated vascular smooth muscle cell infiltration into the atherosclerotic lesion in diabetic mice were observed Metformin alleviated diabetes-induced metabolic disorders and atherosclerosis and also reduced VSMC infiltration in atherosclerotic plaques, while the Pdlim5 phospho-abolished mutant that carried adenovirus S177A-Pdlim5 undermines the protective function of metformin. Metformin 180-189 apolipoprotein E Mus musculus 12-16 34368251-11 2021 The data of ApoE-/- mice showed that increased plasma lipids and aggravated vascular smooth muscle cell infiltration into the atherosclerotic lesion in diabetic mice were observed Metformin alleviated diabetes-induced metabolic disorders and atherosclerosis and also reduced VSMC infiltration in atherosclerotic plaques, while the Pdlim5 phospho-abolished mutant that carried adenovirus S177A-Pdlim5 undermines the protective function of metformin. Metformin 438-447 apolipoprotein E Mus musculus 12-16 34264978-0 2021 Metformin intervention ameliorates AS in ApoE-/- mice through restoring gut dysbiosis and anti-inflammation. Metformin 0-9 apolipoprotein E Mus musculus 41-45 35196199-8 2022 Treatment of APOE-mice with metformin or trehalose ameliorated the loss of retinal function and reduced Bruch"s membrane thickening, enhancing LC3 and LAMP1 labeling in the ocular tissues and restoring LC3-II:LC3-I ratio to WT levels. Metformin 28-37 apolipoprotein E Mus musculus 13-17 35090900-7 2022 Moreover, the metformin administration increased the levels of transcriptional factor NRF-1 and TFAM, mtDNA, and most mitochondrial complex subunits in apoE-TR mice. Metformin 14-23 apolipoprotein E Mus musculus 152-156 33915432-11 2021 We show that metformin protected against HFD-induced atherosclerosis and enhanced plaque stability in apoE-/- mice. Metformin 13-22 apolipoprotein E Mus musculus 102-106 33915432-0 2021 Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE-/- mice. Metformin 0-9 apolipoprotein E Mus musculus 105-109 33411680-9 2020 In vivo, administration of metformin increased the levels of lncRNA-ANRIL, suppressed VSMC phenotypic switching, and prevented the development of atherosclerotic plaque in Apoe-/- mice fed with western diet. Metformin 27-36 apolipoprotein E Mus musculus 172-176 33915432-9 2021 In this study, we first investigated whether metformin could protect against atherogenesis via enhancing autophagy in high fat diet (HFD)-induced apoE-/- mice. Metformin 45-54 apolipoprotein E Mus musculus 146-150 32667970-7 2021 Metformin at a clinically relevant concentration (10muM) evoked AMPK-dependent and ATF1-dependent increases in Hmox1, Nr1h2 (Lxrb), Abca1, Apoe, Igf1 and Pdgf, increases in several M2-markers and decreases in Nos2, in murine bone marrow macrophages. Metformin 0-9 apolipoprotein E Mus musculus 139-143 33411680-10 2020 These protective effects of metformin were abolished by infecting Apoe-/- mice with adenovirus expressing lncRNA-ANRIL shRNA. Metformin 28-37 apolipoprotein E Mus musculus 66-70 31467666-0 2019 Metformin represses the pathophysiology of AAA by suppressing the activation of PI3K/AKT/mTOR/autophagy pathway in ApoE-/- mice. Metformin 0-9 apolipoprotein E Mus musculus 115-119 31955370-1 2020 INTRODUCTION: The aim of our study was to determine the effect of metformin administration on juvenile type 1 diabetes mellitus and atherosclerosis in apolipoprotein E null (ApoE-/-) mice and to explore the mechanism involved. Metformin 66-75 apolipoprotein E Mus musculus 151-167 31518877-0 2019 Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE-/- mice. Metformin 0-9 apolipoprotein E Mus musculus 128-132 31518877-10 2019 CONCLUSIONS: Metformin inhibited NLRP3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE-/- mice, which at least partially through activation of AMPK and regulation of thioredoxin-1/thioredoxin-interacting protein. Metformin 13-22 apolipoprotein E Mus musculus 119-123 30909226-0 2019 Metformin Therapy Aggravates Neurodegenerative Processes in ApoE-/- Mice. Metformin 0-9 apolipoprotein E Mus musculus 60-64 30894020-0 2019 Metformin treatment improves the spatial memory of aged mice in an APOE genotype-dependent manner. Metformin 0-9 apolipoprotein E Mus musculus 67-71 30894020-6 2019 These findings suggest that metformin can improve the cognitive performance of aged mice in an APOE genotype-dependent manner, which provides empirical insights into the clinical value of metformin for ApoE4- and age-related AD prevention and treatment.-Zhang, J., Lin, Y., Dai, X., Fang, W., Wu, X., Chen, X. Metformin 28-37 apolipoprotein E Mus musculus 95-99 30894020-6 2019 These findings suggest that metformin can improve the cognitive performance of aged mice in an APOE genotype-dependent manner, which provides empirical insights into the clinical value of metformin for ApoE4- and age-related AD prevention and treatment.-Zhang, J., Lin, Y., Dai, X., Fang, W., Wu, X., Chen, X. Metformin 188-197 apolipoprotein E Mus musculus 95-99 30894020-7 2019 Metformin treatment improves the spatial memory of aged mice in an APOE genotype-dependent manner. Metformin 0-9 apolipoprotein E Mus musculus 67-71 30909226-12 2019 Thus, metformin-associated lipogenesis as well as inflammation aggravated neurodegenerative processes in ApoE- /- mice. Metformin 6-15 apolipoprotein E Mus musculus 105-109 29502204-8 2018 Administration of metformin enhanced pAP-2alpha level, reduced miR-124 expression, and increased P4Halpha1 and collagens in carotid atherosclerotic plaque in diabetic Apoe-/- mice. Metformin 18-27 apolipoprotein E Mus musculus 167-171 25552600-2 2015 In this study, we investigated the molecular mechanisms responsible for monocyte-to-macrophage differentiation and, subsequently, the effect of metformin in regressing angiotensin II (Ang-II)-mediated atheromatous plaque formation in ApoE(-/-) mice. Metformin 144-153 apolipoprotein E Mus musculus 234-238 29366775-9 2018 Furthermore, a chronic low dose administration of metformin significantly attenuated vascular aging and inhibited age-associated atherosclerotic plaque formation in ApoE-/- mice. Metformin 50-59 apolipoprotein E Mus musculus 165-169 28145471-5 2017 Results showed that in PA-treated HUVECs and HFD-fed ApoE-/- mice, combination of metformin and liraglutide at lower dose significantly improved endothelial dysfunction compared with the single treatment. Metformin 82-91 apolipoprotein E Mus musculus 53-57 29499335-7 2018 Metformin-mediated activation of AMPK was able to significantly abrogate cholesterol uptake by inhibiting SREBP2-M. Interestingly, although metformin administration attenuated angiotensin (Ang)-II-impaired lipid homeostasis in both aorta and liver tissues of ApoE-/- mice, the results indicate that SREBP2 through LDLR regulates lipid homeostasis in aorta but not in liver tissue. Metformin 0-9 apolipoprotein E Mus musculus 259-263 29499335-7 2018 Metformin-mediated activation of AMPK was able to significantly abrogate cholesterol uptake by inhibiting SREBP2-M. Interestingly, although metformin administration attenuated angiotensin (Ang)-II-impaired lipid homeostasis in both aorta and liver tissues of ApoE-/- mice, the results indicate that SREBP2 through LDLR regulates lipid homeostasis in aorta but not in liver tissue. Metformin 140-149 apolipoprotein E Mus musculus 259-263 27737949-4 2017 Metformin treatments markedly reduced mitochondrial fragmentation, mitigated mitochondrial-derived superoxide release, improved endothelial-dependent vasodilation, inhibited vascular inflammation, and suppressed atherosclerotic lesions in streptozotocin (STZ)-induced diabetic ApoE-/- mice. Metformin 0-9 apolipoprotein E Mus musculus 277-281 27737949-6 2017 In contrast, AMPK-alpha2 deficiency abolished the effects of metformin on Drp1 expression, oxidative stress, and atherosclerosis in diabetic ApoE-/-/AMPK-alpha2-/- mice, indicating that metformin exerts an antiatherosclerotic action in vivo via the AMPK-mediated blockage of Drp1-mediated mitochondrial fission. Metformin 61-70 apolipoprotein E Mus musculus 141-145 27256105-6 2016 Conversely, chronic administration of metformin, which activated AMPK, markedly reduced atherosclerotic calcification and Runx2 expression in ApoE(-/-) mice but had less effects in ApoE(-/-)/AMPKalpha1(-/-) mice. Metformin 38-47 apolipoprotein E Mus musculus 142-146 26712380-0 2016 Influence of metformin on mitochondrial subproteome in the brain of apoE knockout mice. Metformin 13-22 apolipoprotein E Mus musculus 68-72 26712380-5 2016 The quantitative assessment of the brain mitoproteome in apoE(-/-) revealed the changes in 10 proteins expression as compared to healthy C57BL/6J mice and 25 proteins expression in metformin-treated apoE(-/-) mice. Metformin 181-190 apolipoprotein E Mus musculus 199-203 25552600-9 2015 Metformin attenuated Ang-II-induced atheromatous plaque formation and aortic aneurysm in ApoE(-/-) mice partly by reducing monocyte infiltration. Metformin 0-9 apolipoprotein E Mus musculus 89-93 22960565-0 2012 Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin. Metformin 88-97 apolipoprotein E Mus musculus 44-60 25527624-4 2014 METHODS AND RESULTS: Using ApoE-/- C57BL/6J mice, we found that metformin attenuates atherosclerosis and vascular senescence in mice fed a high-fat diet and prevents the upregulation of angiotensin II type 1 receptor by a high-fat diet in the aortas of mice. Metformin 64-73 apolipoprotein E Mus musculus 27-31 23531341-10 2013 Furthermore, we show that 7-day treatment with metformin in naive mice leads to an increase in ApoE expression in the sciatic nerve. Metformin 47-56 apolipoprotein E Mus musculus 95-99 22960565-5 2012 Thus, we used a proteomic approach to investigate the effect of metformin on liver mitochondria of apolipoprotein E knockout (apoE(-/-)) mice, an animal model of NAFLD. Metformin 64-73 apolipoprotein E Mus musculus 99-115 22960565-6 2012 Two-dimensional electrophoresis coupled with mass spectrometry was applied to study the changes in liver mitochondrial protein expression in 6-month old metformin-treated apoE(-/-) mice as compared to non-treated animals. Metformin 153-162 apolipoprotein E Mus musculus 171-175